Powered By
Based on current evidence, maximizing treatment duration on first-line therapy for HR+/HER2- metastatic breast cancer optimizes disease control, progression-free survival (PFS), and quality of life.
*
*
True
False
Evidence demonstrates that treatment efficacy decreases with each subsequent line of therapy.
In HR+/HER2- metastatic breast cancer, approximately how much does median PFS decline from 1L to 2L?
*
*
~20%
~30%
~40%
~50%
~60%
During first-line treatment with aromatase inhibitors, patients with HR+/HER2- metastatic breast cancer may develop ESR1 mutations that confer endocrine resistance.
*
*
True
False
ESR1 mutation detection during first-line aromatase inhibitor treatment increases the risk of progression within 3 months by approximately:
*
*
2x
3x
5x
When patients with HR+/HER2- metastatic breast cancer progress from first-line to second-line therapy, what happens to their health-related quality of life (HRQoL)?
*
*
HRQoL improves in second-line due to newer, better-tolerated agents
HRQoL remains stable with no significant changes
HRQoL deteriorates significantly across multiple QoL domains
HRQoL changes are unpredictable with no consistent pattern
Ongoing studies, such as SERENA-6, are evaluating oral SERDs as a potential first-line treatment approach that help delay endocrine resistance by targeting estrogen receptor (ER) degradation in HR+/HER2- metastatic breast cancer.
*
*
True
False
Back
1/3
Next
Correct Answers
*
*
*
*
*